Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at Truist Financial

Truist Financial began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report published on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $18.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on VNDA. UBS Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. Jefferies Financial Group boosted their price target on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright boosted their target price on Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Finally, Wall Street Zen downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $14.90.

Vanda Pharmaceuticals Stock Down 3.5%

Shares of Vanda Pharmaceuticals stock opened at $7.91 on Thursday. The business has a fifty day simple moving average of $7.58 and a 200 day simple moving average of $5.99. The stock has a market cap of $467.56 million, a PE ratio of -2.12 and a beta of 0.55. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). The company had revenue of $57.22 million for the quarter, compared to the consensus estimate of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%. Research analysts predict that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos sold 156,235 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.17, for a total transaction of $1,276,439.95. Following the completion of the transaction, the chief executive officer owned 2,704,496 shares of the company’s stock, valued at $22,095,732.32. This represents a 5.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Kevin Patrick Moran sold 42,442 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total transaction of $350,995.34. Following the transaction, the chief financial officer directly owned 411,380 shares of the company’s stock, valued at $3,402,112.60. This represents a 9.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 314,342 shares of company stock valued at $2,583,985 in the last 90 days. 10.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in VNDA. Torren Management LLC bought a new position in Vanda Pharmaceuticals in the fourth quarter valued at $25,000. Russell Investments Group Ltd. boosted its stake in shares of Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 5,328 shares during the last quarter. CWM LLC boosted its stake in shares of Vanda Pharmaceuticals by 424.6% during the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 7,575 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Vanda Pharmaceuticals by 3,010.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock valued at $92,000 after acquiring an additional 10,055 shares in the last quarter. Finally, Jain Global LLC acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at about $94,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Trending Headlines about Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Truist initiated coverage with a “Buy” and an $18 price target (roughly double current levels), a prominent bullish read that can attract buyers and trading volume. Truist starts Vanda at Buy $18 (Benzinga)
• Positive Sentiment: HC Wainwright reiterated a Buy and published detailed 2027 quarterly EPS forecasts plus a $24 price target — another high upside projection that supports constructive sentiment among growth/biotech investors. HC Wainwright issues estimates, Buy $24 PT
• Positive Sentiment: Regulatory procedure win: the FDA granted a formal evidentiary public hearing on the CDER refusal for Vanda’s sNDA for HETLIOZ in jet?lag disorder — an uncommon, high?visibility forum that could improve approval odds if Vanda presents a strong case. Vanda Announces FDA Grants Landmark Hearing for HETLIOZ (PR Newswire)
• Neutral Sentiment: Analyst landscape is mixed: several firms maintain Buy/Overweight calls and high targets (average ~$14.90), but ratings are not unanimous — constructive overall but not a consensus blowout. MarketBeat analyst summary
• Neutral Sentiment: HC Wainwright’s EPS cadence (quarterly 2027 estimates) gives a clearer path for modeling cash burn and potential milestones, useful for valuation but not an immediate catalyst by itself. HC Wainwright research note (MarketBeat)
• Negative Sentiment: Coordinated insider selling: CEO Mihael Polymeropoulos, CFO Kevin Moran, CMO Joakim Wijkstrom and multiple SVPs disclosed substantial sales on/around March 2 (combined proceeds in the low?millions), which often pressures shares and triggers investor concern about insiders reducing exposure. Vanda’s Top Brass Quietly Unload a Wave of Shares (TipRanks)
• Negative Sentiment: SEC filings now formalize the insider transactions (individual ownership reductions 5–10% for some officers), removing ambiguity about size and timing and increasing short?term selling pressure as investors parse motives (tax planning vs. signal). SEC filing — CEO ownership disclosure

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.